Blog · Evidence, in plain language

GLP-1 medicines and mental health: what we tell patients.

Patients at this practice take GLP-1 medicines prescribed elsewhere, for diabetes and for weight management, and they ask us what the headlines mean for their mental health care. This is the answer we give, with the sources behind it.

By Karel Winner, DNP, PMHNP-BC · Published October 4, 2026

This post is education from the practice, not medical advice. It summarizes published research and a regulator's review. It is not a recommendation about any individual's medicines.

The short answer

In January 2026, the U.S. Food and Drug Administration finished a two-year review of GLP-1 medicines (the class that includes semaglutide and tirzepatide) and suicidal thoughts. Its analysis of 91 placebo-controlled trials, covering 107,910 patients, found no increased risk of suicidal thoughts or behaviors, and no increase in anxiety, depression, irritability, or psychosis. A separate review of health records for about 2.24 million people found no increased risk of intentional self-harm. The FDA asked the makers of the weight-loss versions to remove the suicidal thoughts warning from their labels.

Independent research points the same way. A meta-analysis of 86 randomized trials with 133,378 participants found psychiatric problems at essentially the same rate on these medicines as off them. So the answer we give patients is: the strongest evidence available says these medicines do not raise the risk of depression or suicidal thoughts, and they are not, on current evidence, a reason to avoid mental health care or to change a working psychiatric regimen.

Why we still ask about them at intake

A reassuring safety profile does not make a medicine irrelevant to your care here. These medicines slow stomach emptying, which can change how some oral medicines are absorbed, so they belong on the medication list we review with you, alongside everything else you take. Weight and appetite changes can also carry real emotional weight, and a history with food, eating, or body image changes how a new prescription should be monitored. Tell us about any medicine another clinician prescribes, including these. Complete lists make for safer prescribing.

What we watch together

Mood is part of every follow-up at this practice, whatever medicines are on the list. If your mood shifts after any change, a new medicine, a dose change, a life event, that is visit material, and it is worth raising early rather than at the next scheduled appointment. One Swedish national study even found fewer episodes of worsening depression and anxiety during the months patients were taking a GLP-1 medicine than during months they were not. We mention it because patients ask, and we are equally clear that it is a signal researchers are still testing, not a reason to take these medicines for mood. They are not psychiatric treatments.

Read more, by door

This practice has two clinical doors, and each keeps its own blog. For the medication-focused read on this topic, PsychMed Care, the medication management door, has published GLP-1 medicines and mood, checked against the evidence. For the combined therapy and medication perspective, psych.us has published the GLP-1 question, answered with the actual evidence. When reading has done all it can, the booking page is the next step.

Sources

The summary above rests on the sources below, all published in 2026.

U.S. Food and Drug Administration, Drug Safety Communication, January 13, 2026: the FDA review of GLP-1 medicines and suicidal thoughts and behaviors, and its request to remove that warning language from the weight-loss labels. Medscape's report of the FDA announcement.

Han and colleagues, Diabetes, Obesity and Metabolism (2026): a systematic review and meta-analysis of 86 randomized trials with 133,378 participants, on GLP-1 medicines and psychiatric disorders. PubMed record.

Swedish national cohort study, The Lancet Psychiatry (2026): GLP-1 use and worsening mental illness in people with depression and anxiety. The Lancet Psychiatry.

Systematic review of psychiatric safety, Cureus (2026): 11 studies covering more than 4.9 million patients. PubMed record.

Please read this part

This post is educational and does not create a treatment relationship. Research findings describe large groups and cannot predict an individual's response to any medicine. Patients of this practice who notice mood changes after starting a new medicine, from any prescriber, should raise it at their next visit or sooner. Anyone having thoughts of harming themselves should use the crisis options below immediately.

If you are having thoughts of harming yourself, help is available now: call or text 988, text HOME to 741741 for Crisis Text Line, or see the crisis page.